Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: A computational approach

Frontiers in Pharmacology

Volumn 6, Issue OCT, 2015, Pages

  Platania, Chiara B M ^a   Paola, Luisa Di ^b   Leggio, Gian M ^a   Romano, Giovanni L ^a   Drago, Filippo ^a   Salomone, Salvatore ^a   Bucolo, Claudio ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Aflibercept; Bevacizumab; Diabetic retinopathy; Molecular dynamics; Ranibizumab

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN A;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CALCULATION; CLINICAL PRACTICE; CONTROLLED STUDY; HUMAN; HYDROGEN BOND; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR MECHANICS; PROTEIN PROTEIN INTERACTION; RETINA DISEASE; STATIC ELECTRICITY; SURFACE AREA;

EID: 84947268569     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2015.00248     Document Type: Article

References (65)

1. Amadei, A., Linssen, A. B., and Berendsen, H. J. (1993). Essential dynamics of proteins. Proteins 17, 412-425. doi: 10.1002/prot.340170408
2. Baker, N. A., Sept, D., Joseph, S., Holst, M. J., and McCammon, J. A. (2001). Electrostatics of nanosystems: application to microtubules and the ribosome. Proc. Natl. Acad. Sci. U.S.A. 98, 10037-10041. doi: 10.1073/pnas.181342398
3. Balakrishnan, R. (2004). The energy of a graph. Linear Algebra Appl. 387, 287-295. doi: 10.1016/j.laa.2004.02.038
4. Berendsen, H. J. C., Grigera, J. R., and Straatsma, T. P. (1987). The missing term in effective pair potentials. J. Phys. Chem. 91, 6269-6271. doi: 10.1021/j100308a038
5. Carmeliet, P., and Jain, R. K. (2011). Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298-307. doi: 10.1038/nature10144
6. Chandler, D. (2005). Interfaces and the driving force of hydrophobic assembly. Nature 437, 640-647. doi: 10.1038/nature04162
7. Cheatham, T. E., Miller, J. L., Fox, T., Darden, T. A., and Kollman, P. A. (1995). Molecular-dynamics simulations on solvated biomolecular systems-the particle mesh ewald method leads to stable trajectories of DNA, Rna, and proteins. J. Am. Chem. Soc. 117, 4193-4194. doi: 10.1021/ja00119a045
8. Chen, Y., Wiesmann, C., Fuh, G., Li, B., Christinger, H. W., McKay, P., et al. (1999). Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J. Mol. Biol. 293, 865-881. doi: 10.1006/jmbi.1999.3192
9. Cheng, T. M., Blundell, T. L., and Fernandez-Recio, J. (2007). pyDock: electrostatics and desolvation for effective scoring of rigid-body protein-protein docking. Proteins 68, 503-515. doi: 10.1002/prot.21419
10. Chung, A. S., and Ferrara, N. (2011). Developmental and pathological angiogenesis. Annu. Rev. Cell Dev. Biol. 27, 563-584. doi: 10.1146/annurev-cellbio-092910-154002
11. Clackson, T., and Wells, J. A. (1995). A hot spot of binding energy in a hormone-receptor interface. Science 267, 383-386. doi: 10.1126/science.7529940
12. Copeland, R. A. (2011). Conformational adaptation in drug-target interactions and residence time. Future Med. Chem. 3, 1491-1501. doi: 10.4155/fmc.11.112
13. Corrada, D., and Colombo, G. (2013). Energetic and dynamic aspects of the affinity maturation process: characterizing improved variants from the bevacizumab antibody with molecular simulations. J. Chem. Inf. Model. 53, 2937-2950. doi: 10.1021/ci400416e
14. De Ruvo, M., Giuliani, A., Paci, P., Santoni, D., and Di Paola, L. (2012). Shedding light on protein-ligand binding by graph theory: the topological nature of allostery. Biophys. Chem. 165-166, 21-29. doi: 10.1016/j.bpc.2012.03.001
15. Di Paola, L., De Ruvo, M., Paci, P., Santoni, D., and Giuliani, A. (2013). Protein contact networks: an emerging paradigm in chemistry. Chem. Rev. 113, 1598-1613. doi: 10.1021/cr3002356
16. Dror, R. O., Jensen, M. Ø., Borhani, D. W., and Shaw, D. E. (2010). Exploring atomic resolution physiology on a femtosecond to millisecond timescale using molecular dynamics simulations. J. Gen. Physiol. 135, 555-562. doi: 10.1085/jgp.200910373
17. Eisenberg, D., and McLachlan, A. D. (1986). Solvation energy in protein folding and binding. Nature 319, 199-203. doi: 10.1038/319199a0
18. Feenstra, K. A., Hess, B., and Berendsen, H. J. C. (1999). Improving efficiency of large time-scale molecular dynamics simulations of hydrogen-rich systems. J. Comput. Chem. 20, 786-798.
19. Gabb, H. A., Jackson, R. M., and Sternberg, M. J. (1997). Modelling protein docking using shape complementarity, electrostatics and biochemical information. J. Mol. Biol. 272, 106-120. doi: 10.1006/jmbi.1997.1203
20. Genheden, S., and Ryde, U. (2010). How to obtain statistically converged MM/GBSA results. J. Comput. Chem. 31, 837-846. doi: 10.1002/jcc.21366
21. Genheden, S., and Ryde, U. (2012). Will molecular dynamics simulations of proteins ever reach equilibrium? Phys. Chem. Chem. Phys. 14, 8662-8677. doi: 10.1039/c2cp23961b
22. Hanout, M., Ferraz, D., Ansari, M., Maqsood, N., Kherani, S., Sepah, Y. J., et al. (2013). Therapies for neovascular age-related macular degeneration: current approaches and pharmacologic agents in development. Biomed Res. Int. 2013:830837. doi: 10.1155/2013/830837
23. Hess, B. (2002). Convergence of sampling in protein simulations. Phys. Rev. 65:031910. doi: 10.1103/physreve.65.031910
24. Hess, B. (2008). P-LINCS: a parallel linear constraint solver for molecular simulation. J. Chem. Theory Comput. 4, 116-122. doi: 10.1021/ct700200b
25. Hess, B., Bekker, H., Berendsen, H. J. C., and Fraaije, J. G. E. M. (1997). LINCS: a linear constraint solver for molecular simulations. J. Comput. Chem. 18, 1463-1472.
26. Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., et al. (2002). VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. U.S.A. 99, 11393-11398. doi: 10.1073/pnas.172398299
27. Holz, F. G., Schmitz-Valckenberg, S., and Fleckenstein, M. (2014). Recent developments in the treatment of age-related macular degeneration. J. Clin. Invest. 124, 1430-1438. doi: 10.1172/JCI71029
28. Humphrey, W., Dalke, A., and Schulten, K. (1996). VMD: visual molecular dynamics. J. Mol. Graph. Model. 14, 33-38. doi: 10.1016/0263-7855(96)00018-5
29. Iyer, S., Darley, P. I., and Acharya, K. R. (2010). Structural insights into the binding of vascular endothelial growth factor-B by VEGFR-1(D2): recognition and specificity. J. Biol. Chem. 285, 23779-23789. doi: 10.1074/jbc.M110.130658
30. Jiménez-García, B., Pons, C., and Fernández-Recio, J. (2013). pyDockWEB: a web server for rigid-body protein-protein docking using electrostatics and desolvation scoring. Bioinformatics 29, 1698-1699. doi: 10.1093/bioinformatics/btt262
31. Jorgensen, W. L., Maxwell, D. S., and Tiradorives, J. (1996). Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J. Am. Chem. Soc. 118, 11225-11236. doi: 10.1021/ja9621760
32. Kar, P., Lipowsky, R., and Knecht, V. (2013). Importance of polar solvation and configurational entropy for design of antiretroviral drugs targeting HIV-1 protease. J. Phys. Chem. B 117, 5793-5805. doi: 10.1021/jp3085292
33. Kollman, P. A., Massova, I., Reyes, C., Kuhn, B., Huo, S., Chong, L., et al. (2000). Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc. Chem. Res. 33, 889-897. doi: 10.1021/ar000033j
34. Kukic, P., Farrell, D., McIntosh, L. P., García-Moreno, E. B., Jensen, K. S., Toleikis, Z., et al. (2013). Protein dielectric constants determined from NMR chemical shift perturbations. J. Am. Chem. Soc. 135, 16968-16976. doi: 10.1021/ja406995j
35. Kumari, R., Kumar, R., and Lynn, A. (2014). g_mmpbsa-A GROMACS tool for high-throughput MM-PBSA calculations. J. Chem. Inf. Model. 54, 1951-1962. doi: 10.1021/ci500020m
36. Leppänen, V. M., Prota, A. E., Jeltsch, M., Anisimov, A., Kalkkinen, N., Strandin, T., et al. (2010). Structural determinants of growth factor binding and specificity by VEGF receptor 2. Proc. Natl. Acad. Sci. U.S.A. 107, 2425-2430. doi: 10.1073/pnas.0914318107
37. Li, X., Xu, G., Wang, Y., Xu, X., Liu, X., Tang, S., et al. (2014). Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study. Ophthalmology 121, 1740-1747. doi: 10.1016/j.ophtha.2014.03.026
38. Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G. S., Jaffe, G. J., Grunwald, J. E., et al. (2012). Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119, 1388-1398. doi: 10.1016/j.ophtha.2012.03.053
39. Muller, Y. A., Chen, Y., Christinger, H. W., Li, B., Cunningham, B. C., Lowman, H. B., et al. (1998). VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. Structure 6, 1153-1167. doi: 10.1016/S0969-2126(98)00116-6
40. Neugebauer, J., Reiher, M., Kind, C., and Hess, B. A. (2002). Quantum chemical calculation of vibrational spectra of large molecules-Raman and IR spectra for buckminsterfullerene. J. Comput. Chem. 23, 895-910. doi: 10.1002/jcc.10089
41. Nicholls, A., Sharp, K. A., and Honig, B. (1991). Protein folding and association-insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins 11, 281-296. doi: 10.1002/prot.340110407
42. Ozboyaci, M., Gursoy, A., Erman, B., and Keskin, O. (2011). Molecular recognition of H3/H4 histone tails by the tudor domains of JMJD2A: a comparative molecular dynamics simulations study. PLoS ONE 6:e14765. doi: 10.1371/journal.pone.0014765
43. Pan, A. C., Borhani, D. W., Dror, R. O., and Shaw, D. E. (2013). Molecular determinants of drug-receptor binding kinetics. Drug Discov. Today 18, 667-673. doi: 10.1016/j.drudis.2013.02.007
44. Papadopoulos, N., Martin, J., Ruan, Q., Rafique, A., Rosconi, M. P., Shi, E., et al. (2012). Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15, 171-185. doi: 10.1007/s10456-011-9249-6
45. Pronk, S., Páll, S., Schulz, R., Larsson, P., Bjelkmar, P., Apostolov, R., et al. (2013). GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics 29, 845-854. doi: 10.1093/bioinformatics/btt055
46. Richmond, T. J. (1984). Solvent accessible surface area and excluded volume in proteins. Analytical equations for overlapping spheres and implications for the hydrophobic effect. J. Mol. Biol. 178, 63-89. doi: 10.1016/0022-2836(84)90231-6
47. Schmidt-Erfurth, U., Kaiser, P. K., Korobelnik, J. F., Brown, D. M., Chong, V., Nguyen, Q. D., et al. (2014). Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 121, 193-201. doi: 10.1016/j.ophtha.2013.08.011
48. Schwede, T., Kopp, J., Guex, N., and Peitsch, M. C. (2003). SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res. 31, 3381-3385. doi: 10.1093/nar/gkg520
49. Spiliotopoulos, D., Spitaleri, A., and Musco, G. (2012). Exploring PHD fingers and H3K4me0 interactions with molecular dynamics simulations and binding free energy calculations: AIRE-PHD1, a comparative study. PLoS ONE 7:e46902. doi: 10.1371/journal.pone.0046902
50. Stewart, M. W. (2014a). Anti-VEGF therapy for diabetic macular edema. Curr. Diab. Rep. 14:510. doi: 10.1007/s11892-014-0510-4
51. Stewart, M. W. (2014b). Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF. Expert Rev. Clin. Pharmacol. 7, 167-180. doi: 10.1586/17512433.2014.884458
52. Tasdighian, S., Di Paola, L., De Ruvo, M., Paci, P., Santoni, D., Palumbo, P., et al. (2014). Modules identification in protein structures: the topological and geometrical solutions. J. Chem. Inf. Model. 54, 159-168. doi: 10.1021/ci400218v
53. Teicher, B. A. (2011). Antiangiogenic agents and targets: a perspective. Biochem. Pharmacol. 81, 6-12. doi: 10.1016/j.bcp.2010.09.023
54. Vishveshwara, S., Ghosh, A., and Hansia, P. (2009). Intra and inter-molecular communications through protein structure network. Curr. Protein Pept. Sci. 10, 146-160. doi: 10.2174/138920309787847590
55. Wade, R. C., Gabdoulline, R. R., Lüdemann, S. K., and Lounnas, V. (1998). Electrostatic steering and ionic tethering in enzyme-ligand binding: insights from simulations. Proc. Natl. Acad. Sci. U.S.A. 95, 5942-5949. doi: 10.1073/pnas.95.11.5942
56. Wang, X., and Yang, J. (2013). Analysis of the binding affinity of vascular endothelial growth factor A (VEGF) to ranibizumab, aflibercept and bevacizumab. Invest. Ophthalmol. Vis. Sci. 54. Abstract retrieved from ARVO Annual Meeting Abstracts database. (Accession No. 1961).
57. Wang, Y., Zheng, Y., Zhang, W., Yu, H., Lou, K., Zhang, Y., et al. (2007). Polymorphisms of KDR gene are associated with coronary heart disease. J. Am. Coll. Cardiol. 50, 760-767. doi: 10.1016/j.jacc.2007.04.074
58. Welti, J., Loges, S., Dimmeler, S., and Carmeliet, P. (2013). Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J. Clin. Invest. 123, 3190-3200. doi: 10.1172/JCI70212
59. Wu, Z., Zhou, P., Li, X., Wang, H., Luo, D., Qiao, H., et al. (2013). Structural characterization of a recombinant fusion protein by instrumental analysis and molecular modeling. PLoS ONE 8:e57642. doi: 10.1371/journal.pone.0057642
60. Xu, L., Lu, T., Tuomi, L., Jumbe, N., Lu, J., Eppler, S., et al. (2013). Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Invest. Ophthalmol. Vis. Sci. 54, 1616-1624. doi: 10.1167/iovs.12-10260
61. Yadav, S., Demeule, B., Liu, J., and Shire, S. J. (2014). The relative affinities of ranibizumab and aflibercept for vascular endothelial growth factor A (VEGF)-an analytical ultracentrifugation study. Invest Ophthalmol. Vis. Sci. Abstract retrieved from ARVO Annual Meeting Abstracts database. (Accession No. 1942).
62. Yang, J., Wang, X., Fuh, G., Yu, L., Wakshull, E., Khosraviani, M., et al. (2014). Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A. Mol. Pharm. 11, 3421-3430. doi: 10.1021/mp500160v
63. Yu, L., Liang, X. H., and Ferrara, N. (2011). Comparing protein VEGF inhibitors: in vitro biological studies. Biochem. Biophys. Res. Commun. 408, 276-281. doi: 10.1016/j.bbrc.2011.04.014
64. Zheng, J., Ma, B., Tsai, C. J., and Nussinov, R. (2006). Structural stability and dynamics of an amyloid-forming peptide GNNQQNY from the yeast prion sup-35. Biophys. J. 91, 824-833. doi: 10.1529/biophysj.106.083246
65. Zhou, H. X. (2001). Disparate ionic-strength dependencies of on and off rates in protein-protein association. Biopolymers 59, 427-433. doi: 10.1002/1097-0282(200111)59:6<427::AID-BIP1047>3.0.CO;2-7